A variety of cytotoxic drugs (e.g., platinum, taxane), targeted drugs (e.g., gefitinib, erlotinib) and immune checkpoint inhibitors (e.g., PD1/PDL-1 inhibitors) have been used in the treatment of non-small cell lung cancer, and have achieved certain some curative effect [18–22]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.